NSE: SYNGENE | BSE: 539268

Slowing Down Stock

Download real time

631.60 8.75 (1.40%)

34.25% Fall from 52W High

395.8K NSE+BSE Volume

NSE 01 Oct, 2025 3:50 PM (IST)

25,449.7

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Syngene International Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SYNGENE, BSE:539268 Syngene International Ltd.

Syngene International Ltd.

05 Jan 2021

631.60

1.40%

Syngene Ltd - A Behemoth in the making

Syngene International Ltd.

Monarch Networth Capital Limited

Long standing multi-year client relationships with 25% of 360+ clients associated with Syngene for more than 5 years. Capex ramp up in core business (Discovery, Development, RnD) to...

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

23 Oct 2020

631.60

1.40%

Syngene Intl

Buy: Syngene International Ltd.

Dolat Capital

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

23 Oct 2020

631.60

1.40%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Syngene International Ltd. has lost -29.70% in the last 1 Year

Syngene International Ltd.

23 Jul 2020

631.60

1.40%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Revenues grew at ~16% CAGR in FY16-20 to | 2012 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It has a pool...

Syngene International Ltd. has lost -29.70% in the last 1 Year

Syngene International Ltd.

14 May 2020

631.60

1.40%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

24 Jan 2020

631.60

1.40%

Biologics/Small molecules progressing well; Research Services growth moderate

Neutral: Syngene International Ltd.

Motilal Oswal

In addition to CRAMS (Syngene)/Biosimilars, BIOS is building another lever i.e. Small molecules for growth over the next 4-5 years. Revenue increased 13% YoY to INR17.5b (in-line) in 3QFY20, mainly led by strong growth in Biologics (+31% YoY; 34% of sales) and Small Molecules Research Services (30% of sales) grew 11% YoY to INR5.2b. Aspart BLA is likely to Gross margin is likely to improve in the coming quarters with ramp up in production of Pegfilgrastim and better traction in Trastuzumab. Over FY19-22, we expect earnings CAGR of 28%, led by a CAGR of 36% in Biologics and 17% in Small molecules, with a 360bp margin improvement. Further, Syngene is well positioned to move from contract research to contract manufacturing and thus Over FY19-22, we expect earnings CAGR of 20%, led by a CAGR of 36% in Biologics and 17% in Small molecules, with a 360bp margin improvement.

Syngene International Ltd. is trading below all available SMAs

Syngene International Ltd.

24 Jan 2020

631.60

1.40%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Revenues grew at ~21% CAGR in FY15-19 to | 1826 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It owns a pool...

Number of FII/FPI investors decreased from 332 to 279 in Jun 2025 qtr

Syngene International Ltd.

26 Jul 2019

631.60

1.40%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Integrated business model, customer stickiness to the fore Revenues grew at ~21% CAGR in FY15-19 to | 1826 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It owns a pool...